# The Columbia PCC for CureGN: the Cure Glomerulonephropathy network

> **NIH NIH U01** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $597,934

## Abstract

Project Summary/Abstract
Primary glomerular diseases including minimal change disease (MCD), focal segmental
glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IGAN), and membranous
nephropathy (MN) account for 10% of end-stage renal disease and are associated with significant
morbidity and mortality in both adults and children. Despite the significant disease burden
associated with these heterogeneous disorders, disease pathogenesis, natural history, predictors
of clinical outcomes and predictors of response to therapy remain incompletely defined. To
address these gaps in knowledge, the CureGN consortium assembled a large consortium of 70
clinical study sites, nephrologists, scientists with diverse expertise, affected patients and
advocacy groups, the biopharmaceutical industry, federal funding agencies, and regulatory
agencies. CureGN is conducting a prospective, longitudinal observational study, successfully
enrolling and retaining a race and ethnicity-balanced cohort of nearly 2400 adult and pediatric
participants with IgAN, FSGS, MN and MCD. We propose to maintain and enhance the CureGN
Consortium infrastructure and its ancillary study program to accelerate patient-relevant
glomerular disease research. We will continue our core prospective, longitudinal observational
study of glomerular disease patients, enrolling additional subjects by a recruit-to-replace strategy
to maintain an active cohort of 2400, while banking and curating high quality clinical data and
biomaterials. This foundational work is being conducted by a refined study administrative structure
and a well-functioning collaboration between the Data Coordinating Center (at Arbor Research
Collaborative for Health and the University of Michigan) and four Participating Clinical Centers
(managed at the University of Pennsylvania, Columbia University, University of North Carolina,
and the Midwest Pediatric Consortium). CureGN sits at the nexus of multiple domains that are
collaborating in overcoming the barriers to improving care for glomerular disease patients. By its
now experienced scientific working groups, its publications committee, and its ancillary study
infrastructure, by enabling modern analytical approaches in multiple relatable knowledge
domains, by administering a research opportunity pool in conjunction with NephCure Kidney
International, by continuing refinement of study instruments, by enhancing career development
activities, and by convening patient and public-private collaborations for validating and
implementing precision medicine-based therapies, the resource created by CureGN should
accelerate improving care of glomerular disease patients.

## Key facts

- **NIH application ID:** 10691635
- **Project number:** 3U01DK100876-10S1
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** ALI G GHARAVI
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $597,934
- **Award type:** 3
- **Project period:** 2013-09-16 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10691635

## Citation

> US National Institutes of Health, RePORTER application 10691635, The Columbia PCC for CureGN: the Cure Glomerulonephropathy network (3U01DK100876-10S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10691635. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*